Table 1 Patient characteristics

From: Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

Patient number

Age (year)

Sex

Time of prior events

Prior histology

Prior treatment

Time of last relapse

Histology at relapse

 1

60

M

02-2000

GBM

S, R, C

10-2000

GBM

 2

11

F

02-1997

AA

S, R, C

05-2001

PXA

   

05-1999

AA

   

 3

17

F

01-1989

PA

S, R

06-2001

GBM

   

03-1999

AA

S, R, C

  

 4

15

M

02-1998

GBM

S, R, C

06-2001

GBM

 5

34

F

07-2001

AA

S, R

07-2001

GBM

 6

53

M

02-2001

GBM

S, R, C

12-2001

GBM

 7

78

M

05-1999

GBM

S, R, C

02-2002

GBM

 8

62

F

08-2001

GBM

S, R, C

04-2002

GBM

 9

39

F

01-1995

ODG III

S, R, C

05-2002

GBM

   

03-2000

ODG IV

   

10

30

M

09-1999

AA

S, R, C

05-2002

GBM

11

15

F

12-1990

ALL

C

06-2002

No vital tissue after tumour bleeding

   

10-2001

GBM

S, R

  

12

62

F

4-9-2001

GBM

S, R, C

09-2002

GBM

  1. AA=anaplastic astrocytoma; ALL=acute lymphatic leukaemia; C=chemotherapy; F=female; GBM=glioblastoma multiforme; III=WHO grade 3r, IV=WHO grade 4r; M=male; ODG=oligodendroglioma; PA=pilocytic astrocytoma; PXA=malignant pleomorphic xanthoastrocytoma; R=radiotherapy; S=surgery.